ASCO 2022 | Dose-escalation results from the first-in-solid-tumor trial of modakafusp alfa

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the mechanism of action of the novel immuno-cytokine, modakafusp alfa, which consists of two interferon molecules fused to an anti-CD38 monoclonal antibody. Modakafusp alfa is currently being investigated in a Phase Ib/II trial, with dose escalation results being presented at ASCO 2022. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.